Indication
Indolent B Cell Non-Hodgkin Lymphoma
2 clinical trials
1 product
2 drugs
Clinical trial
A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin LymphomaStatus: Completed, Estimated PCD: 2019-07-11
Product
Imprime PGGDrug
VarlilumabClinical trial
A Phase 1/2 Study of N-803 in Patients With Relapse/Refractory Indolent B Cell Non-Hodgkin Lymphoma in Conjunction With RituximabStatus: Terminated, Estimated PCD: 2020-12-13
Drug
N-803